Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1 (5-Year IF – 2.0)
Journal Citation Indicator (JCI) (2023) – 0.4
Scopus CiteScore – 3.7 (CiteScore Tracker – 4.2)
Index Copernicus  – 171.00; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2017, vol. 26, nr 6, September, p. 953–959

doi: 10.17219/acem/63999

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

The evaluation of the changes in enzymatic antioxidant reserves and lipid peroxidation in chosen parts of the brain in an animal model of Parkinson disease

Ewa B. Romuk1,A,B,C,D, Wioletta Szczurek1,B,C,D, Michał Oleś2,B,C, Artur Gabrysiak3,B,C, Marta Skowron1,B,C, Przemysław Nowak2,A,E,F, Ewa Birkner1,E,F

1 Department of Biochemistry, Medical University of Silesia, School of Medicine with the Division of Dentistry, Zabrze, Poland

2 Department of Toxicology and Health Protection, Medical University of Silesia, School of Public Health, Katowice, Poland

3 FRYDA Medical Laboratory Ltd., Poland

Abstract

Background. Parkinson’s disease is a progressive neurodegenerative disorder, characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta. The causes of Parkinson’s disease are not fully understood; however, increasing evidence implicates oxidative stress.
Objectives. The study was aimed at assessing the nature of the changes in the oxidation-antioxidant balance in the cerebral cortex, striatum, hippocampus, thalamus, and cerebellum in a rat model of Parkinson’s disease (PD).
Material and Methods. Sixteen male Wistar rats were divided into 2 groups: Icontrol, IIParkinson’s disease. The 8-weeks-old animals were decapitated, their brains removed and the following structures dissected and then frozen for further biochemical assays: cerebral cortex, striatum, hippocampus, thalamus and cerebellum. The activities of: the catalase (CAT), glutathione reductase (GR), glutathione peroxidase (GPx), glutathione S-transferase (GST), superoxide dismutase (SOD) and the isoenzymes: Cu/ZnSOD and MnSOD; together with the malondialdehyde (MDA) and the total oxidative status (TOS) concentrations were measured in each structure.
Results. A significantly increased activities of SOD, Cu/ZnSOD, GST and reduced GR activity and an increase of MDA concentration were observed in the striatum of PD rats, comparing to the control group, combined with a significantly reduced activities of GR,SOD, Cu/ZnSOD and an increased GPX activity and MDA concentration in the hippocampus, a significantly lower GR, SOD, MnSOD, Cu/ZnSOD, and GST activities in the cerebral cortex. A significantly lower GR activity, higher CAT activity and MDA concentration in the thalamus and a significantly increased GR activity in the cerebellum were observed in PD rats compared to the corresponding control group.
Conclusion. Oxidative stress in PD involves many brain structures and various antioxidant enzymes and oxidative status parameters become dysfunctional, depending on the area of the brain, which might reflect the complexity of the clinical symptoms of PD.

Key words

oxidative stress, Parkinson disease, brain, antioxidant

References (30)

  1. Chinta SJ, Andersen JK. Redox imbalance in Parkinson’s disease. Biochim Biophys Acta. 2008;1780:1362–1367.
  2. Yuan H, Zheng JC, Liu P, Zhang SF, Xu JY, Bai LM. Pathogenesis of Parkinson’s disease: Oxidative stress, environmental impact factors and inflammatory processes. Neurosci Bull. 2007;23:125–130.
  3. Dias V, Junn E, Mouradian MM. The role of oxidative stress in Parkinson’s disease. J Parkinsons Dis. 2013;3:461–491.
  4. Zhou C, Huang Y, Przedborski S. Oxidative stress in Parkinson’s disease: A mechanism of pathogenic and therapeutic significance. Ann N Y Acad Sci. 2008;1147:93–104.
  5. Kostrzewa RM, Kostrzewa JP, Brus R, Kostrzewa RA, Nowak P. Proposed animal model of severe Parkinson’s disease: Neonatal 6-hydroxydopamine lesion of dopaminergic innervation of striatum. J Neural Transm Suppl. 2006;70:277–279.
  6. Richterich R. Chemia kliniczna. Warszawa: PZWL;1971.
  7. Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med. 1967;70:158–169.
  8. Habig, WH, Jakoby WB. Assays for differentiation of glutathione S-transferases. Methods Enzymol. 1981;77:398–405.
  9. Oyanagui Y. Reevaluation of assay methods and establishment of kit for superoxide dismutase activity. Anal Biochem. 1984;142:290–296.
  10. Aebi H. Catalase in vitro. Methods Enzymol. 1984;105:121–126.
  11. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979;95:351–358.
  12. Niranjan R. The role of inflammatory and oxidative stress mechanisms in the pathogenesis of Parkinson’s disease: Focus on astrocytes. Mol Neurobiol. 2014;49:28–38.
  13. Ross BM, Moszczynska A, Erlich J, Kish SJ. Low activity of key phospholipid catabolic and anabolic enzymes in human substantia nigra: Possible implications for Parkinson’s disease. Neuroscience. 1998;83:791–798.
  14. Kaur H, Chauhan S, Sandhir R. Protective effect of lycopene on oxidative stress and cognitive decline in rotenone induced model of Parkinson’s disease. Neurochem Res. 2011;36:1435–1443.
  15. Rodriguez-Rocha H, Garcia-Garcia A, Pickett C, et al. Compartmentalized oxidative stress in dopaminergic cell death induced by pesticides and complex I inhibitors: Distinct roles of superoxide anion and superoxide dismutases. Free Radic Biol Med. 2013;61:370–383.
  16. Iglesias-González J, Sánchez-Iglesias S, Méndez-Álvarez E, et al. Differential toxicity of 6-hydroxydopamine in SH-SY5Y human neuroblastoma cells and rat brain mitochondria: Protective role of catalase and superoxide dismutase. Neurochem Res. 2012;37:2150–2160.
  17. Choi J, Rees HD, Weintraub ST, Levey AI, Chin LS, Li L. Oxidative modifications and aggregation of Cu, Zn-superoxide dismutase associated with Alzheimer and Parkinson diseases. J Biol Chem. 2005;280:1648–1655.
  18. Gu F, Chauhan V, Chauhan A. Glutathione redox imbalance in brain disorders. Curr Opin Clin Nutr Metab Care. 2015;18:89–95.
  19. Pearce RK, Owen A, Daniel S, Jenner P, Marsden CD. Alterations in the distribution of glutathione in the substantia nigra in Parkinson’s disease. J Neural Transm. 1997;104:661–677.
  20. Zhou ZD, Lim TM. Roles of glutathione (GSH) in dopamine (DA) oxidation studied by improved tandem HPLC plus ESI-MS. Neurochem Res. 2009;34:316–326.
  21. Smeyne M, Smeyne RJ. Glutathione metabolism and Parkinson’s disease. Free Radic Biol Med. 2013;62:13–25.
  22. Göttlich M, Münte TF, Heldmann M, Kasten M, Hagenah J,Krämer UM. Altered resting state brain networks in Parkinson’s disease. PLoS One. 2013;8:e77336.
  23. Wang Y, Kan H, Yin Y, et al. Protective effects of ginsenoside Rg1 on chronic restraint stress induced learning and memory impairments in male mice. Pharmacol Biochem Behav. 2014;120:73–81.
  24. Camicioli R, Moore MM, Kinney A, Corbridge E, Glassberg K, Kaye JA. Parkinson’s disease is associated with hippocampal atrophy. Mov Disord. 2003;18:784–790.
  25. Saleem S, Tabassum S, Ahmed S, Perveen T, Haider S. Senescence related alteration in hippocampal biogenic amines produces neuropsychological deficits in rats. Pak J Pharm Sci. 2014;27:837–845.
  26. Che Y, Zhou Z, Shu Y, et al. Chronic unpredictable stress impairs endogenous antioxidant defense in rat brain. Neurosci Lett. 2015;584:208–213.
  27. Chhunchha B, Fatma N, Kubo E, Rai P, Singh SP, Singh DP. Curcumin abates hypoxia-induced oxidative stress based-ER stress-mediated cell death in mouse hippocampal cells (HT22) by controlling Prdx6 and NF-κB regulation. Am J Physiol Cell Physiol. 2013;304:C636-C655.
  28. van Mierlo TJ, Chung C, Foncke EM, Berendse HW, van den Heuvel OA. Depressive symptoms in Parkinson’s disease are related to decreased hippocampus and amygdala volume. Mov Disord. 2015;30:245–252.
  29. Varela C, Sherman SM. Differences in response to serotonergic activation between first and higher order thalamic nuclei. Cereb Cortex. 2009;19:1776–1786.
  30. Ebner TJ, Pasalar S. Cerebellum predicts the future motor state. Cerebellum. 2008;7:583–588.
© Wroclaw Medical University